Surgery to Remove Recurrent Ovarian Cancer Provides Favorable Survival
- From: J <nexsw@nvalid,anon>
- Date: Wed, 18 Apr 2007 13:16:28 -0400
http://patient.cancerconsultants.com/CancerNews.aspx
Surgery to Remove Recurrent Ovarian Cancer Provides Favorable Survival
(03/30/2007)
Surgery to Remove Recurrent Ovarian Cancer Provides Favorable Survival
According to an article recently published in Gynecologic Oncology,
patients with ovarian cancer who have a recurrence in a lymph node have
favorable survival when the involved lymph node is entirely or almost
entirely removed.
Ovarian cancer is the deadliest form of gynecologic cancer. Initial
surgical removal of as much cancer as possible is necessary to obtain
optimal outcomes. Standard treatment for recurrent ovarian cancer may
consist of surgery, chemotherapy, and/or radiation therapy. Researchers
continue to evaluate optimal ways to treat recurrences of ovarian cancer.
Researchers from the John Hopkins Medical Institutions and the Cedar-Sinai
Medical Center recently conducted a clinical study to evaluate the
potential effectiveness of the surgical removal of cancer that had
recurred in a lymph node. This study included 25 patients, the majority of
whom had initially been diagnosed with advanced, aggressive ovarian
cancer. Participants had received prior surgery followed by chemotherapy
with a platinum agent (Platinol® [cisplatin] or Paraplatin®
[carboplatin]). Optimal cytoreduction (surgery to remove cancer with 1
centimeter or less of cancer remaining) was achieved in all patients.
* The median length of hospitalization was four days.
* There were no significant side effects associated with surgery.
* At a median of 19 months, 40% of patients were alive with no
evidence of cancer, 28% were alive with evidence of cancer, and 32% had
died of the disease.
* The median overall survival following surgery was 37 months.
The researchers concluded that optimal cytoreductive surgery for patients
with ovarian cancer that has recurred in a single lymph node ?is
associated with a favorable long-term survival outcome.? Patients with
recurrent ovarian cancer may wish to discuss with their physician their
individual risks and benefits of surgery.
Reference: Santillan A, Karam A, Li A, et al. Secondary cytoreductive
surgery for isolated nodal recurrence in patients with epithelial ovarian
cancer. Gynecologic Oncology. 2007; 104: 686-690.
.
- Prev by Date: The prognostic value of anaemia in locally advanced head and neck cancer
- Next by Date: Quality of life as a primary end point in oncology
- Previous by thread: The prognostic value of anaemia in locally advanced head and neck cancer
- Next by thread: Quality of life as a primary end point in oncology
- Index(es):
Relevant Pages
|
